arrow
M

Marzia Del Re

Saint Camillus International University of Medical and Health Sciences
H指数:45
被引数:6,576

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The administration of proton pump inhibitors with the CDK4/6 inhibitor abemaciclib does not affect the clinical outcome of metastatic breast cancer patients

质子泵抑制剂与CDK4/6抑制剂abemaciclib联用不影响转移性乳腺癌患者的临床结局

2026-04-220
PRE
Liquid Biopsy in Non-Metastatic Prostate Cancer: Clinical Evidence and Future Directions

液体活检在非转移性前列腺癌中的应用:临床证据与未来方向

Cancers
IF4.4
2026-03-010
OAAI
Pharmacokinetic interactions and clinical implications of PPIs and CDKIs in breast cancer: a systematic review and meta-analysis

质子泵抑制剂和细胞周期蛋白依赖性激酶抑制剂在乳腺癌中的药代动力学相互作用及临床意义:一项系统评价和Meta分析

2025-12-300
OAAI
Late endocrine-metabolic complications in survivors of young adult and adult-onset cancers: comprehensive evaluation and strategies for management. An Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical review

年轻成年及成年发病癌症幸存者的晚期内分泌-代谢并发症:全面评估与管理策略。意大利医学肿瘤学会(AIOM)、意大利医学糖尿病学会(AMD)、意大利糖尿病学会(SID)、意大利内分泌学会(SIE)、意大利药理学学会(SIF)多学科批判性综述

2025-12-030
OAAI
Liquid biopsy in Oncology: Results of a Delphi consensus study endorsed by the AIOM-SIAPEC/IAP-SIBioC-SIF Italian scientific societies

肿瘤学中的液体活检:意大利科学学会AIOM-SIAPEC/IAP-SIBioC-SIF赞助的德尔菲共识研究的结果

2025-12-010
PRE
A novel comprehensive cancer genome profiling for non-metastatic prostate cancer: study protocol with FPG500 to detect actionable alterations representative of progressive disease

非转移性前列腺癌的新型综合基因组图谱分析:使用FPG500检测代表疾病进展的可操作突变的研究方案

2025-10-100
PRE
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus report

激素受体阳性/HER2阴性转移性乳腺癌的演变格局(EVOLVE):一项意大利Delphi共识报告

2025-06-060
OA
Clinical relevance and methodological approach for the assessment of drug–drug interactions in cancer patients: a position statement from the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pharmacology (SIF)

癌症患者药物相互作用评估的临床相关性与方法学路径:意大利医学肿瘤学会(AIOM)和意大利药理学学会(SIF)的立场声明

2025-06-010
OA
Glycemic control and cancer outcomes in oncologic patients with diabetes: an Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical view
2024-06-276
OAAI